Session 4: What are the strategic and technological manufacturing and supply chain advances required to enable commercial CAR-T cell therapies to scale beyond 20% of eligible patients?

Advanced Therapies Week 2027 · 20 January 2027 · 11:00–12:00 · Theatre 4

Session 4: What are the strategic and technological manufacturing and supply chain advances required to enable commercial CAR-T cell therapies to scale beyond 20% of eligible patients? was a session at Advanced Therapies Week 2027 on 20 January 2027 in San Diego, with 5 speakers on record.

Speakers

• Boro Dropulić — Speaker Executive Director, Caring Cross; CEO, Vector BioMed
• Lindsey MacDonald — Speaker Manager of CCTTs Data Analytics Unit, University of Pennsylvania Health System, Penn Medicine
• Rohin Iyer — Speaker Senior Director, Global Cell and Gene Therapy Operations, Marken
• Caitlin Cahill — Speaker Administration Director, University of Pennsylvania Health Systems, Penn Medicine
• Deborah Hursh — Speaker Consultant, Hursh Cell Therapy Consulting